BRPI0509220A - método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio - Google Patents
método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélioInfo
- Publication number
- BRPI0509220A BRPI0509220A BRPI0509220-5A BRPI0509220A BRPI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- epithelium
- modern
- kit
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 title abstract 3
- 206010013774 Dry eye Diseases 0.000 title abstract 3
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 230000016396 cytokine production Effects 0.000 title 1
- 210000000981 epithelium Anatomy 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract 1
- 229960003744 loteprednol etabonate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
"MéTODO, FORMULAçãO OFTáLMICA E KIT PARA PARA O TRATAMENTO DE OLHO RESSECADO MODERADO A GRAVE; MéTODO PARA O TRATAMENTO DE OLHO RESSECADO CRÈNICO; E MéTODOS PARA REDUZIR A VERMELHIDãO E A PRODUçãO DE CITOCINAS INFLAMATóRIAS POR CéLULAS NO EPITéLIO". Descrito em modalidades no presente documento está um método de tratamento de olho ressecado moderado a grave em um paciente necessitando do mesmo, sendo que o método compreende administrar etabonato de loteprednol de forma tópica no paciente em um veículo aceitável do ponto de vista oftálmico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55616104P | 2004-03-25 | 2004-03-25 | |
| PCT/US2005/009761 WO2005094836A2 (en) | 2004-03-25 | 2005-03-24 | Use of loteprednol etabonate for the treatment of dry eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509220A true BRPI0509220A (pt) | 2007-09-04 |
Family
ID=34963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509220-5A BRPI0509220A (pt) | 2004-03-25 | 2005-03-24 | método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050222110A1 (pt) |
| EP (2) | EP2127655A1 (pt) |
| JP (1) | JP2007530573A (pt) |
| KR (1) | KR20070004750A (pt) |
| CN (1) | CN1964719B (pt) |
| AT (1) | ATE441419T1 (pt) |
| AU (1) | AU2005229006B9 (pt) |
| BR (1) | BRPI0509220A (pt) |
| CA (1) | CA2560824A1 (pt) |
| DE (1) | DE602005016392D1 (pt) |
| ES (1) | ES2330762T3 (pt) |
| MX (1) | MXPA06010849A (pt) |
| TW (1) | TW200602030A (pt) |
| WO (1) | WO2005094836A2 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| CN101317847B (zh) * | 2007-06-06 | 2010-10-13 | 深圳市瑞谷医药技术有限公司 | 一种眼用或耳鼻用药物组合物及其用途 |
| US20090239836A1 (en) * | 2008-03-24 | 2009-09-24 | Mary Lee Ciolkowski | Multifunctional Ophthalmic Compositions |
| US8835410B2 (en) | 2011-05-10 | 2014-09-16 | Bodor Laboratories, Inc. | Treatment of eyelid dermatitis |
| WO2013133980A1 (en) * | 2012-03-05 | 2013-09-12 | Bausch & Lomb Incorporated | Nitroxy derivatives of soft steroids |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CA2900680C (en) | 2013-02-20 | 2021-08-10 | Kala Pharmaceuticals, Inc. | Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN106279325A (zh) * | 2015-05-27 | 2017-01-04 | 天津金耀集团有限公司 | 一种依碳氯替泼诺新晶型及其制备方法 |
| CN106279324A (zh) * | 2015-05-27 | 2017-01-04 | 天津金耀集团有限公司 | 依碳氯替泼诺一水合物及其晶型与制备方法 |
| CN106892952A (zh) * | 2015-12-21 | 2017-06-27 | 天津金耀集团有限公司 | 一种依碳氯替泼诺新晶型及其制备方法 |
| CN106892953A (zh) * | 2015-12-21 | 2017-06-27 | 天津金耀集团有限公司 | 依碳氯替泼诺一水合物及其晶型与制备方法 |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| JP2020523406A (ja) * | 2017-05-19 | 2020-08-06 | オクジェン アイエヌシー． | 眼科用組成物および使用方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US104A (en) | 1836-12-10 | Revolving hokse-rake | ||
| US5075A (en) | 1847-04-17 | Improvement in cultivators | ||
| US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US6610675B1 (en) | 1980-07-10 | 2003-08-26 | Nicholas S. Bodor | Inactive metabolite approach to soft drug design |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| US6096052A (en) * | 1998-07-08 | 2000-08-01 | Ovion, Inc. | Occluding device and method of use |
| US7073504B2 (en) * | 1996-12-18 | 2006-07-11 | Ams Research Corporation | Contraceptive system and method of use |
| TW503113B (en) | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
| KR100508227B1 (ko) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | 로테프레드놀에타보네이트수성현탁액 |
| DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| CN1239161C (zh) | 2001-05-21 | 2006-02-01 | 爱尔康公司 | 可用于治疗干眼疾病的类固醇 |
| EP1438037A1 (en) * | 2001-10-11 | 2004-07-21 | Alcon, Inc. | Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| EP1476135A1 (en) * | 2002-02-22 | 2004-11-17 | Pharmacia Corporation | Ophthalmic formulation with gum system |
| US7074426B2 (en) * | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| AU2003301129A1 (en) * | 2002-12-20 | 2004-07-22 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
| WO2004073748A1 (ja) * | 2003-02-20 | 2004-09-02 | Senju Pharmaceutical Co., Ltd. | 水性懸濁液剤 |
| US20050182039A1 (en) * | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
-
2005
- 2005-03-24 WO PCT/US2005/009761 patent/WO2005094836A2/en not_active Ceased
- 2005-03-24 EP EP09168219A patent/EP2127655A1/en not_active Withdrawn
- 2005-03-24 DE DE602005016392T patent/DE602005016392D1/de not_active Expired - Lifetime
- 2005-03-24 AU AU2005229006A patent/AU2005229006B9/en not_active Ceased
- 2005-03-24 US US11/088,481 patent/US20050222110A1/en not_active Abandoned
- 2005-03-24 AT AT05729286T patent/ATE441419T1/de not_active IP Right Cessation
- 2005-03-24 JP JP2007505155A patent/JP2007530573A/ja active Pending
- 2005-03-24 ES ES05729286T patent/ES2330762T3/es not_active Expired - Lifetime
- 2005-03-24 CN CN2005800160300A patent/CN1964719B/zh not_active Expired - Fee Related
- 2005-03-24 EP EP05729286A patent/EP1744759B1/en not_active Expired - Lifetime
- 2005-03-24 BR BRPI0509220-5A patent/BRPI0509220A/pt active Search and Examination
- 2005-03-24 KR KR1020067019449A patent/KR20070004750A/ko not_active Ceased
- 2005-03-24 MX MXPA06010849A patent/MXPA06010849A/es active IP Right Grant
- 2005-03-24 CA CA002560824A patent/CA2560824A1/en not_active Abandoned
- 2005-03-25 TW TW094109520A patent/TW200602030A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007530573A (ja) | 2007-11-01 |
| ATE441419T1 (de) | 2009-09-15 |
| KR20070004750A (ko) | 2007-01-09 |
| ES2330762T3 (es) | 2009-12-15 |
| HK1102551A1 (en) | 2007-11-30 |
| TW200602030A (en) | 2006-01-16 |
| US20050222110A1 (en) | 2005-10-06 |
| WO2005094836A2 (en) | 2005-10-13 |
| DE602005016392D1 (de) | 2009-10-15 |
| AU2005229006B9 (en) | 2011-05-19 |
| EP2127655A1 (en) | 2009-12-02 |
| CA2560824A1 (en) | 2005-10-13 |
| CN1964719A (zh) | 2007-05-16 |
| CN1964719B (zh) | 2010-05-05 |
| EP1744759A2 (en) | 2007-01-24 |
| AU2005229006B2 (en) | 2011-01-20 |
| AU2005229006A1 (en) | 2005-10-13 |
| WO2005094836A3 (en) | 2006-01-26 |
| MXPA06010849A (es) | 2007-03-08 |
| EP1744759B1 (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509220A (pt) | método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio | |
| AR034619A1 (es) | Formulaciones de olopatadine para administracion topica | |
| WO2021126320A9 (en) | Treatment of amyotrophic lateral sclerosis and related disorders | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| NZ701559A (en) | Compositions comprising povidone-iodine | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| CY1109763T1 (el) | Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης | |
| CR8453A (es) | Metodo para el tratamiento de trastornos oftalmicos | |
| WO2010004435A3 (en) | Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders | |
| EE05315B1 (et) | Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette nhtud imetajal esineva seksuaalse funktsioonihire ravimiseks v?i m?jutamiseks | |
| EA200700074A1 (ru) | Способ повышения скорости заживления повреждения ( варианты ), устройство доставки перекиси водорода и композиция для лечения повреждений у млекопитающих | |
| WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
| AR033207A1 (es) | Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac | |
| EA200701017A1 (ru) | Применение рибозы-цистеина для лечения гипоксии | |
| EP1495755B8 (fr) | Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale liée au vieillissement ou à une irradiation | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| ATE448779T1 (de) | Methode zur behandlung trockener augen und uveitis | |
| WO2003051301A3 (en) | USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY | |
| EA201200753A1 (ru) | Фармацевтическая композиция для лечения заболеваний мочевого пузыря | |
| MX2022010584A (es) | Metodo y kit para tratar infecciones de la piel. | |
| AR070466A1 (es) | Composiciones de gemifloxacina oculares, procedimiento de preparacion y uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |